Floatz logo

LENVATINIB

TACE

Zhejiang Cancer HospitalSmall moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the TACE cohort.

Asset / SponsorPhaseRating
Theprubicin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3B
Ethiodized Oil
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3B
Tislelizumab
Zhejiang Cancer Hospital
Phase 2B
Inno-206
First Affiliated Hospital, Sun Yat-Sen University
Phase 3B
Tuvonralimab
Anhui Provincial Hospital
Phase 2CCC

View all 12 →

Same molecule, other indications

LENVATINIB is also rated in:

Primary Peritoneal Cavity CancerDormant
BBB
Indicative ·
73 / 100
View asset →
Stage IIB Breast CancerDormant
BBB
Indicative ·
73 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →